Ra Pharmaceuticals, Inc. Common Stock
RARX
RARX was delisted on the 1st of April, 2020.
66 hedge funds and large institutions have $131M invested in Ra Pharmaceuticals, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 18 reducing their positions, and 15 closing their positions.
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
11% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 18
3% more funds holding
Funds holding: 64 → 66 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
43% less capital invested
Capital invested by funds: $230M → $131M (-$98.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$5.83M |
| 2 |
BlackRock
New York
|
+$3.79M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.23M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$574K |
| 5 |
PP
PDT Partners
New York
|
+$569K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.06M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.43M |
| 3 |
VMI
VHCP Management II
New York
|
-$2.77M |
| 4 |
Millennium Management
New York
|
-$2.3M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.78M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCA
76
Secor Capital Advisors
New York
| – | -$203K | -13,889 | Closed |
|
|
CS
77
Credit Suisse
Zurich,
Switzerland
| – | -$148K | -10,151 | Closed |
|
78
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$16K | -1,069 | Closed |
|
79
UBS Group
Zurich,
Switzerland
| – | -$6K | -393 | Closed |
|
|
MA
80
MUFG Americas
New York
| – | -$2K | -150 | Closed |
|
81
Bank of Montreal
Toronto,
Ontario, Canada
| – | +$246 | +20 | New |
|
RARX Hedge Fund Activity: Q4 2017 in Review
66 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Ra Pharmaceuticals, Inc. Common Stock (RARX) for Q4 2017, worth a combined $131M — down 43% from $230M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new RARX positions and 15 closed out — a net gain of 2 holders — while 20 added to existing stakes and 18 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $5.83M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.06M sold.
- 66 institutional investors held Ra Pharmaceuticals, Inc. Common Stock (RARX) as of Q4 2017, up from 64 in Q3 2017.
- Funds reported $131M of Ra Pharmaceuticals, Inc. Common Stock stock for Q4 2017, down 43% quarter-over-quarter.
- 17 funds opened new Ra Pharmaceuticals, Inc. Common Stock positions in Q4 2017 and 15 closed out, a net change of +2 holders.
- The largest Ra Pharmaceuticals, Inc. Common Stock buyer in Q4 2017 was Wellington Management Group, an estimated $5.83M added.
- The largest Ra Pharmaceuticals, Inc. Common Stock seller in Q4 2017 was Sectoral Asset Management, an estimated $4.06M sold.
Based on aggregated 13F filings for Q4 2017.